Navigation Links
Kinovate Life Sciences Launches Nittophase?High Performance Solid Support For Oligonucleatide Synthesis

Kinovate Life Sciences, Inc, a provider of tools for oligonucleotide synthesis and gene delivery, announced today that it will officially launch its new NittoPhase?solid support for oligonucleotide synthesis at the TIDES meeting commencing in Boston on May 1st. The joint development of this solid phase support product was announced on November 8th, 2004 by Kinovate’s sole shareholder, Nitto Denko Corporation (Osaka, Japan), a leading multi-national polymer synthesis company and Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), a leader in RNA-based drug discovery and development.

Through utilization of the unparalleled polymer synthesis and R&D capabilities of Nitto Denko Corporation, Isis?outstanding oligonucleotide synthesis and drug development expertise and the worldwide marketing and customer support operations of Kinovate Life Sciences, this new product promises to deliver significantly improved technical and economic outcomes for all segments of the oligonucleotide industry.

Solid support is the base structure used in the synthesis of oligonucleotides, including diagnostic probes and primers, antisense including RNAi, microRNA, DNA-based and aptamer drugs and represents a substantial portion of the cost to manufacture these oligonucleotides.

NittoPhase?has been rigorously tested at both small and large scales, and has been observed to exhibit superior characteristics and performance when compared to other solid supports currently on the market. NittoPhase?has great potential to decrease manufacturing costs due to it’s significantly lower unit cost, as well as potentially higher yield and full length purity, reducing cost-of-goods. NittoPhase?will be commercially available in two grades; NittoPhaseTOS?for high loading applications, and NittoPhaseROS?for lower loading applications. In this way, NittoPhase?offers a solution for the entire spectrum of oligonucleotide synthesis applications.

“Kinovate Life Sciences aims to be a robust p artner to both oligonucleotide manufacturers and drug development companies by providing NittoPhase? a new support with superlative performance at a significantly reduced unit cost. In this way we see considerable potential to make it possible for players of all scales in this industry to meet both long and short term objectives of cost savings, and the eventual development of oligonucleotide drugs that are affordable to patients,?stated Dr. Kenji Matsumoto, President of Kinovate Life Sciences, Inc. “Through our strong collaborative relationship with Isis Pharmaceuticals, we have had access to the very highest standard of technical and analytical resources to ensure that NittoPhase?will deliver unmatched performance.?/p>

“Our internal testing and analysis of NittoPhase?has clearly validated this product in terms of technical and cost performance. As a result of our partnership with Nitto Denko Corporation, Isis is pleased to incorporate NittoPhase?into its own drug development operations going forward,?said B. Lynne Parshall, Executive Vice President and Chief Financial Officer of Isis Pharmaceuticals. “We look forward to participating in the success of NittoPhase? Our product development partnership with Nitto Denko is another example of how Isis has used its expertise in RNA-based drug discovery and development to work with partners in bringing innovative products to the market.?/p>
'"/>

Source:PRWeb


Related biology news :

1. Affymetrix Licenses Microfluidics Technology From Caliper Life Sciences
2. TrueBlue Archive Will Store Raw Life Sciences Data for Proteomics and Drug Testing
3. Sangamo BioSciences demonstrates its ZFP treatment protects cells from HIV infection
4. Affymetrix Launches New Globin-Reduction Kits and Protocol Developed with PreAnalytiX
5. IMF Launches World’s First DNA Database for Myeloma Patients
6. Invitrogen Launches i-Path -- A Unique Systems Biology Platform at BIO 2005
7. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/20/2016)... June 20, 2016 Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring ... involved, it has secured the final acceptance by ... for Managed Access Systems (MAS) installed. Furthermore, Securus ... to be installed by October, 2016. MAS distinguishes ...
(Date:6/9/2016)... 2016 Paris Police Prefecture ... security solution to ensure the safety of people and operations ... the major tournament Teleste, an international technology group ... announced today that its video security solution will be utilised ... up public safety across the country. The system roll-out is ...
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ON , June 27, 2016 /PRNewswire/ - BIOREM Inc. ... has been advised by its major shareholders, Clean Technology ... United States based venture capital ... shares of Biorem (on a fully diluted, as converted ... the disposition of their entire equity holdings in Biorem ...
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
Breaking Biology Technology: